Obstetric Indications for Progestin Therapy
Copyright © 2022 Elsevier Inc. All rights reserved..
Specifically, meta-analyses of randomized trials demonstrate that vaginal progesterone reduces the risk of preterm birth in selected high-risk singleton pregnancies. 17-OHPC may also reduce the risk of recurrent preterm birth in singletons. Finally, one trial suggests that vaginal progesterone may also be beneficial in improving live birth rates in singletons with prior miscarriages and early pregnancy bleeding.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Obstetrics and gynecology clinics of North America - 50(2023), 1 vom: 01. März, Seite 101-107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boelig, Rupsa C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
17 alpha-Hydroxyprogesterone Caproate |
|---|
| Anmerkungen: |
Date Completed 27.02.2023 Date Revised 27.02.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ogc.2022.10.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353289353 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353289353 | ||
| 003 | DE-627 | ||
| 005 | 20231226055643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ogc.2022.10.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353289353 | ||
| 035 | |a (NLM)36822696 | ||
| 035 | |a (PII)S0889-8545(22)00095-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boelig, Rupsa C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Obstetric Indications for Progestin Therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2023 | ||
| 500 | |a Date Revised 27.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Specifically, meta-analyses of randomized trials demonstrate that vaginal progesterone reduces the risk of preterm birth in selected high-risk singleton pregnancies. 17-OHPC may also reduce the risk of recurrent preterm birth in singletons. Finally, one trial suggests that vaginal progesterone may also be beneficial in improving live birth rates in singletons with prior miscarriages and early pregnancy bleeding | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 17-OHPC | |
| 650 | 4 | |a 17-hydroxyprogesterone caproate | |
| 650 | 4 | |a Preterm birth | |
| 650 | 4 | |a Progesterone | |
| 650 | 4 | |a Progestin | |
| 650 | 7 | |a Progesterone |2 NLM | |
| 650 | 7 | |a 4G7DS2Q64Y |2 NLM | |
| 650 | 7 | |a 17 alpha-Hydroxyprogesterone Caproate |2 NLM | |
| 650 | 7 | |a 276F2O42F5 |2 NLM | |
| 650 | 7 | |a Progestins |2 NLM | |
| 650 | 7 | |a Hydroxyprogesterones |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Obstetrics and gynecology clinics of North America |d 1995 |g 50(2023), 1 vom: 01. März, Seite 101-107 |w (DE-627)NLM012977047 |x 1558-0474 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:1 |g day:01 |g month:03 |g pages:101-107 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ogc.2022.10.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 1 |b 01 |c 03 |h 101-107 | ||